The bill introduced on March 20, 2025, aims to amend the Code of West Virginia regarding the classification and scheduling of controlled substances. It proposes the addition of new substances to Schedule I, including Brorphine and various hallucinogenic compounds, while clarifying that fentanyl and carfentanil will remain classified as Schedule II substances. The bill also seeks to remove Norfentanyl from Schedule I and introduces new opioid receptor agonists like 2-Methyl AP-237. Additionally, it addresses errors in the current code to ensure accurate and up-to-date classifications, ultimately enhancing public safety through refined regulations.

Further amendments include updates to Schedules IV and V, with notable insertions such as Alfaxalone, Daridorexant, Zuranolone, and Ganaxolone, as well as the addition of Lorcaserin in Schedule V. The bill also specifies that materials containing Fenfluramine and Dexfenfluramine will be included in these schedules. Alongside these insertions, the bill aims to remove outdated language and correct errors in existing law, ensuring that the classifications reflect current medical and scientific understanding. Overall, the legislation seeks to modernize the regulatory framework for controlled substances while maintaining strict oversight of potentially harmful drugs.

Statutes affected:
Introduced Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212